Skip to main content
Erschienen in:

15.10.2018 | Gynecologic Oncology

Mesothelin as a target for cervical cancer therapy

verfasst von: Korinna Jöhrens, Lea Lazzerini, Jana Barinoff, Jalid Sehouli, Guenter Cichon

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The cell surface glycoprotein Mesothelin is overexpressed in several tumor entities and novel immune-based therapies are currently under the early clinical evaluation for the treatment of malignant pleura mesothelioma, ovarian cancer, and pancreatic cancer. Cervical cancer has not been recognized as a suitable target for Mesothelin-directed immune therapies so far.

Methods

To exploit a possible role of Mesothelin in cervical cancer treatment, we analysed Mesothelin expression in 79 cervical carcinomas and aligned expressions patterns with tumor growth parameters. A novel anti-Mesothelin drug conjugate (Anetumab Ravtansine) was applied for dose-efficiency studies in a Mesothelin positive tumor model for cervical cancer in Scid mice.

Results

In more than three-quarters (77%) of cervical adenocarcinomas, Mesothelin was expressed to high levels. Among squamous cell carcinomas of the cervix uteri expression levels were lower and expression patterns were less intense, but still ranged between 50–60% (57%). A significant correlation between Mesothelin expression levels and tumor grade, metastatic behaviour, and lymph- or hemangiosis was not found. The novel anti-Mesothelin-drug conjugate (Anetumab Ravtansine) showed a substantial dose-dependent therapeutic efficiency in a xenotransplant model for cervical cancer in SCID mice (hela cell tumors). Applying the ADC at a dose of 10 mg/kg twice weekly induced complete tumor regression in 88% of animals within 6 weeks.

Conclusions

Mesothelin should be taken into account as a target in cervical cancer therapy and histological determination of Mesothelin expression should be considered in routine diagnostics of cervical carcinomas.
Literatur
1.
Zurück zum Zitat Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373–381CrossRefPubMed Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373–381CrossRefPubMed
2.
Zurück zum Zitat Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F et al (2016) Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol 7:218–222CrossRefPubMedPubMedCentral Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F et al (2016) Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol 7:218–222CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Reiter Y, Pastan I (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 2:245–252PubMed Reiter Y, Pastan I (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 2:245–252PubMed
5.
Zurück zum Zitat Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149CrossRefPubMed Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149CrossRefPubMed
6.
Zurück zum Zitat Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M et al (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311–3319CrossRefPubMed Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M et al (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311–3319CrossRefPubMed
7.
Zurück zum Zitat Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20PubMedPubMedCentral Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20PubMedPubMedCentral
8.
Zurück zum Zitat Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132–6138CrossRefPubMedPubMedCentral Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132–6138CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A et al (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927–5936CrossRefPubMedPubMedCentral Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A et al (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927–5936CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A et al (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5:208ra147CrossRefPubMedPubMedCentral Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A et al (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5:208ra147CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G et al (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325–1333CrossRefPubMedPubMedCentral Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G et al (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325–1333CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA et al (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6):1537–1548CrossRefPubMed Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA et al (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6):1537–1548CrossRefPubMed
13.
Zurück zum Zitat Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinaoms: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–807CrossRefPubMed Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinaoms: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–807CrossRefPubMed
14.
Zurück zum Zitat Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H (2016) Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs 3:76–86CrossRefPubMedPubMedCentral Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H (2016) Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs 3:76–86CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M et al (2017) Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 8(28):46425–46435PubMedPubMedCentral Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M et al (2017) Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 8(28):46425–46435PubMedPubMedCentral
16.
Zurück zum Zitat Wang Y, Wang L, Li D, Wang HB, Chen QF (2012) Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res 40:2109–2116CrossRefPubMed Wang Y, Wang L, Li D, Wang HB, Chen QF (2012) Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res 40:2109–2116CrossRefPubMed
17.
Zurück zum Zitat Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S et al (2014) Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 9:e114900CrossRefPubMedPubMedCentral Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S et al (2014) Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 9:e114900CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020–1028CrossRefPubMed Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020–1028CrossRefPubMed
19.
Zurück zum Zitat He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ et al (2017) Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 16:63CrossRefPubMedPubMedCentral He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ et al (2017) Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 16:63CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Han SH, Joo M, Kim H, Chang S (2017) Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol Transl Med 51:122–128CrossRefPubMedPubMedCentral Han SH, Joo M, Kim H, Chang S (2017) Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol Transl Med 51:122–128CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13:378–384CrossRefPubMed Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13:378–384CrossRefPubMed
22.
Zurück zum Zitat Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M et al (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195–199CrossRefPubMed Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M et al (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195–199CrossRefPubMed
23.
Zurück zum Zitat Bendell J, Blumenschein G, Zinner R, et al. (2016) First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American 86 clinical cancer drugs 3; no. 2 Bendell J, Blumenschein G, Zinner R, et al. (2016) First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American 86 clinical cancer drugs 3; no. 2
24.
Zurück zum Zitat Hassan et al. (2015) Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (ID 1574; oral presentation). In: 16th World Conference on Lung Cancer WCLC 2015 in Denver, Colorado, September 6–9, 20 Hassan et al. (2015) Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (ID 1574; oral presentation). In: 16th World Conference on Lung Cancer WCLC 2015 in Denver, Colorado, September 6–9, 20
Metadaten
Titel
Mesothelin as a target for cervical cancer therapy
verfasst von
Korinna Jöhrens
Lea Lazzerini
Jana Barinoff
Jalid Sehouli
Guenter Cichon
Publikationsdatum
15.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-018-4933-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den Arbeitsaufwand für Radiologen. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

Präeklampsie-Prophylaxe mit ASS: Suche nach optimaler Dosierung

Der Nutzen einer frühzeitigen Präeklampsie-Prophylaxe mit Acetylsalicylsäure steht außer Frage. Über die optimale Dosierung wird noch diskutiert. Eine Forschungsgruppe aus Schweden deshalb hat verschiedene Einnahmeregime verglichen, mit einem erstaunlichem Ergebnis.

Automatisierte Insulinabgabe hilft postpartal bei Blutzuckerkontrolle

Ergebnisse aus einer Fortsetzung der AiDAPT-Studie sprechen dafür, dass ein HCL („hybrid closed loop“)-System auch in den ersten sechs Monaten nach dem Entbinden eine bessere Blutzuckereinstellung erlaubt als eine Standardinsulinabgabe.  

cfDNA-Screening kann auf maternalen Krebs hinweisen

Unübliche oder nicht auswertbare Resultate des nichtinvasiven Screenings auf fetale Aneuploidie mithilfe der Sequenzierung zellfreier DNA können ein Zeichen für Krebs der Mutter sein. In einer Studie lag die Prävalenz nahe 50%.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.